TrialHaematologica2013

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Srdan Verstovsek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.